Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.80% | 22.56% | 25.45% | 10.65% | 6.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.80% | 22.56% | 25.45% | 10.65% | 6.09% |
| Cost of Revenue | -14.20% | -15.97% | -13.59% | 2.88% | 7.45% |
| Gross Profit | 33.40% | 53.63% | 58.38% | 16.46% | 5.15% |
| SG&A Expenses | 58.05% | 28.55% | -0.27% | -26.06% | -39.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.48% | 14.35% | -1.80% | -15.00% | -26.81% |
| Operating Income | -103.75% | 3.66% | 46.48% | 47.33% | 64.10% |
| Income Before Tax | -479.03% | -193.24% | -15.36% | 13.89% | 85.99% |
| Income Tax Expenses | -105.71% | -29.86% | -113.73% | -- | -- |
| Earnings from Continuing Operations | -460.83% | -190.59% | -13.74% | 13.15% | 85.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -460.83% | -190.59% | -13.74% | 13.15% | 85.54% |
| EBIT | -103.75% | 3.66% | 46.48% | 47.33% | 64.10% |
| EBITDA | -118.72% | 2.07% | 47.31% | 47.67% | 65.25% |
| EPS Basic | -378.65% | -110.44% | 14.60% | 36.69% | 90.50% |
| Normalized Basic EPS | -122.00% | -26.01% | 35.91% | 50.39% | 79.38% |
| EPS Diluted | -264.18% | -81.21% | 21.48% | 40.07% | 87.47% |
| Normalized Diluted EPS | -122.31% | -26.12% | 35.87% | 50.37% | 79.41% |
| Average Basic Shares Outstanding | 41.63% | 39.11% | 34.24% | 25.82% | 25.73% |
| Average Diluted Shares Outstanding | 31.85% | 29.01% | 24.04% | 15.75% | 35.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |